Lakewood-Amedex Biotherapeutics Inc. (NASDAQ:LABT) Short Interest Update

Lakewood-Amedex Biotherapeutics Inc. (NASDAQ:LABT) saw a large increase in short interest during the month of June. As of June 15th, there was short interest totaling 73,164 shares, an increase of 87.5% from the May 31st total of 39,018 shares. Based on an average daily volume of 362,400 shares, the days-to-cover ratio is currently 0.2 days. Currently, 10.5% of the shares of the stock are sold short.

Wall Street Analysts Forecast Growth

Separately, Wall Street Zen cut shares of Lakewood-Amedex Biotherapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 30th.

Lakewood-Amedex Biotherapeutics Trading Up 5.1%

Shares of LABT stock traded up $0.16 on Wednesday, reaching $3.30. 297,245 shares of the stock were exchanged, compared to its average volume of 292,000. The company’s 50 day moving average price is $12.90. Lakewood-Amedex Biotherapeutics has a twelve month low of $2.95 and a twelve month high of $98.20.

Lakewood-Amedex Biotherapeutics Company Profile

We are a biotechnology company focused on leveraging unique, pioneering science to address unmet needs in the treatment of infectious diseases, improving patient outcomes, and significantly reducing the threat posed by antibiotic-resistant bacterial strains, including methicillin resistant Staphylococcus aureus (MRSA), vancomycin resistant Enterococci species (VRE), and others. Antimicrobial resistance (AMR) represents a growing global health crisis, being directly responsible for 1.27 million deaths annually and contributing to nearly 5 million deaths worldwide.